Nucleoside derivatives for treating hepatitis C virus infection

Details Nucleoside derivatives for treating hepatitis C virus infection Nucleoside derivatives for treating hepatitis C virus infection

2008-09-08

2009-12-08

Crane, Lawrence E (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S026230, C536S026260, C536S026700, C536S027200

Reexamination Certificate

active

07629328

ABSTRACT:
Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I:wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein.

REFERENCES:
patent: 5430027 (1995-07-01), Knutsen et al.
patent: 5681941 (1997-10-01), Cook et al.
patent: 5763167 (1998-06-01), Conrad
patent: 5977332 (1999-11-01), Martin
patent: 6211154 (2001-04-01), Scarbourough et al.
patent: 6475985 (2002-11-01), Wagner et al.
patent: 6500946 (2002-12-01), Takamatsu et al.
patent: 6586413 (2003-07-01), Liang et al.
patent: 6660721 (2003-12-01), Devos et al.
patent: 6703394 (2004-03-01), Engelhardt et al.
patent: 6777395 (2004-08-01), Bhat et al.
patent: 7094768 (2006-08-01), Roberts et al.
patent: 7425547 (2008-09-01), Roberts et al.
patent: 7432248 (2008-10-01), Roberts et al.
patent: 2003/0130226 (2003-07-01), Loakes et al.
patent: 2007/0015905 (2007-01-01), LaColla et al.
patent: 2007/0032449 (2007-02-01), LaColla et al.
patent: 1117669 (2001-07-01), None
patent: WO 94/18215 (1994-08-01), None
patent: WO 95/07919 (1995-03-01), None
patent: WO 02/057287 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 03/061576 (2003-07-01), None
patent: WO03/061576 (2003-07-01), None
patent: WO 03/072757 (2003-09-01), None
patent: WO 2004/028481 (2004-04-01), None
patent: WO 2004/065398 (2004-08-01), None
Beigelman et al. “New Syntheses of 2′-C-Methylnucleosides Starting from D-Glucose and D-Ribose” Carbo. Research, 166:219-232 (1987).
Bowler et al., “New Adenosine A3 Ligands Controlling Cytokines,” Drug Development Research, 37, 173 (bottom of col. 2) (Mar. 1996).
Jacobson et al., “Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors,” Drug Development Research, 39(3-4), 289-300 (1996).
Hinshaw, et al. “Pyrrolopyrimidine nucleosides. IV. Synthesis of certain 4, 5-disubstituted-7-(.beta.-D-ribofuranosy 1)pyrrolo[2,3-d]pyrimidine nucleoside antibiotics” J. of Heterocyclic Chemistry 6(2):215-221 CODEN: JHTCAD; ISSN: 0022-152X, (1969) XP002388343.
Hinshaw, et al. “Pyrrolopyrimidine nucleosides. X. Synthesis of 4,5-disubstituted 7-(.beta.-D-ribofuranosyl)pyrrolo[2,3-d]py rimidines related to toyocamycin and sangivamycin” J. of the Chemical Society, Perkin Transactions: Organic and Bio-Organic Chemistry (1972-1999), (13), 1248-53 CODEN: JCPRB4; ISSN: 0300-922X (1975), XP009068854.
Ding, et al. “Synthesis of 2′-beta-C-methyl toyocamycin and sangivamycin analogues as potential HCV inhibitors” Bioorganic & Medicinal Chemistry Letters, Oxford, GB 15(3):725-727 (Feb. 1, 2005).

Affiliated with

Also associated with

Rating

Nucleoside derivatives for treating hepatitis C virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleoside derivatives for treating hepatitis C virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleoside derivatives for treating hepatitis C virus infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4136238